Thorne Healthtech (NASDAQ:THRN) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Thorne Healthtech (NASDAQ:THRN) from a hold rating to a buy rating in a report issued on Wednesday, Zacks.com reports. Zacks Investment Research currently has $7.00 price objective on the stock.

According to Zacks, “Thorne HealthTech is involved in developing solutions for a personalized approach to health and wellbeing. It provides personalized solutions to consumers, health professionals and corporations. The company’s integrated brand includes Thorne and Onegevity. Thorne HealthTech is based in NEW YORK. “

A number of other research analysts also recently issued reports on the stock. Evercore ISI assumed coverage on shares of Thorne Healthtech in a research report on Monday, October 18th. They set an outperform rating and a $13.00 target price on the stock. Royal Bank of Canada initiated coverage on shares of Thorne Healthtech in a research note on Monday, October 18th. They set an outperform rating and a $11.00 price target for the company. Cowen began coverage on shares of Thorne Healthtech in a research note on Monday, October 18th. They set an outperform rating and a $11.00 price target for the company. Finally, Bank of America assumed coverage on Thorne Healthtech in a report on Monday, October 18th. They issued a buy rating and a $11.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $10.60.

NASDAQ THRN opened at $6.41 on Wednesday. The company has a 50 day simple moving average of $7.31. The company has a quick ratio of 1.86, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. Thorne Healthtech has a 12-month low of $5.20 and a 12-month high of $10.13.

Thorne Healthtech (NASDAQ:THRN) last announced its earnings results on Wednesday, November 10th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.03. The company had revenue of $48.01 million for the quarter. As a group, analysts anticipate that Thorne Healthtech will post 0.2 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in Thorne Healthtech in the third quarter valued at approximately $4,264,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Thorne Healthtech during the third quarter valued at approximately $3,963,000. Emerald Advisers LLC bought a new stake in shares of Thorne Healthtech during the third quarter valued at approximately $3,822,000. Monashee Investment Management LLC bought a new stake in shares of Thorne Healthtech during the third quarter valued at approximately $3,082,000. Finally, Scout Investments Inc. increased its holdings in shares of Thorne Healthtech by 32.1% during the fourth quarter. Scout Investments Inc. now owns 264,247 shares of the company’s stock valued at $1,641,000 after acquiring an additional 64,271 shares in the last quarter. 11.81% of the stock is currently owned by institutional investors.

About Thorne Healthtech

Thorne HealthTech is involved in developing solutions for a personalized approach to health and wellbeing. It provides personalized solutions to consumers, health professionals and corporations. The company’s integrated brand includes Thorne and Onegevity. Thorne HealthTech is based in NEW YORK.

Featured Article: Why does the United States have a lingering trade deficit?

Get a free copy of the Zacks research report on Thorne Healthtech (THRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Thorne Healthtech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thorne Healthtech and related companies with MarketBeat.com's FREE daily email newsletter.